An announcement from PYC Therapeutics Limited ( (AU:PYC) ) is now available.
PYC Therapeutics Limited has successfully completed its Entitlement Offer, raising approximately $146 million, which contributes to a cash runway exceeding $200 million. This financial boost will support the company in advancing its pipeline of first-in-class drug candidates, with human safety and efficacy read-outs expected over the next 24 months, potentially strengthening its position in the precision medicine industry.
More about PYC Therapeutics Limited
PYC Therapeutics Limited is a clinical-stage biotechnology company focused on developing RNA therapies to treat genetic diseases. The company leverages its proprietary drug delivery platform to enhance the effectiveness of precision medicines, particularly targeting monogenic diseases, which have a higher likelihood of success in clinical development.
YTD Price Performance: -17.56%
Average Trading Volume: 575,974
Technical Sentiment Signal: Hold
Current Market Cap: A$550.9M
See more insights into PYC stock on TipRanks’ Stock Analysis page.